# A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

> **NCT05839626** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 32 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma
- Amyloid Light-chain Amyloidosis

## Interventions

- **DRUG:** SAR445514

## Key facts

- **NCT ID:** NCT05839626
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-15
- **Primary completion:** 2025-05-26
- **Final completion:** 2025-05-26
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Early discontinuation based on sponsor decision not driven by any safety concerns.
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05839626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05839626, "A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05839626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*